Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 35 - Antineoplastic agents
Patents for A61P 35 - Antineoplastic agents (221,099)
03/2014
03/13/2014WO2014039855A1 Combination therapy of a type ii anti-cd20 antibody with a selective bcl-2 inhibitor
03/13/2014WO2014039839A1 Method of treating leukemia
03/13/2014WO2014039682A1 Antibody formulations and uses thereof
03/13/2014WO2014039595A1 Imidazopyridazine jak3 inhibitors and their use for the treatment of inflammatory and autoimmune diseases
03/13/2014WO2014039504A1 Bolaamphiphilic compounds, compositions and uses thereof
03/13/2014WO2014039500A1 Bolaamphiphilic compounds, compositions and uses thereof
03/13/2014WO2014039421A1 Isotopologues of 3-(5-amino-2-methyl-4-oxoquinazolin-3(4h)-yl) piperidine-2-6-dione and methods of preparation thereof
03/13/2014WO2014039375A1 Method of adjuvant cancer treatment
03/13/2014WO2014038890A1 Fusion protein comprising axl and composition for treating cancer comprising same
03/13/2014WO2014038888A1 Fusion protein comprising ros1 and composition for treating cancer comprising same
03/13/2014WO2014038887A1 Fusion protein comprising fgfr2 and composition for treating cancer comprising same
03/13/2014WO2014038881A2 Protein kinase inhibitor comprising pyridine derivatives
03/13/2014WO2014038866A1 Composition for treating angiogenic diseases using extracellular matrix membrane of cartilage-derived cell, and transplant material for cornea or conjunctiva
03/13/2014WO2014038606A1 Crystal of dispiropyrrolidine derivative
03/13/2014WO2014037751A1 Pharmacologically active compounds
03/13/2014WO2014037750A1 Inhibitor compounds
03/13/2014WO2014037332A1 Inhibitors of alpha6 integrin/e-cadherin complex and their therapeutic and diagnostic use in cancer
03/13/2014WO2014036971A1 Methods of using immunomodulating peptide for treating or preventing inflammatory related diseases
03/13/2014WO2014036954A1 Transmucosal administration of taxanes
03/13/2014WO2014036953A1 Polymorphs of aromatic urea for use in antineoplastic medicament and methods for preparing the polymorphs
03/13/2014WO2014036897A1 Imidazoline derivatives, preparation methods thereof, and their applications in medicine
03/13/2014WO2014036807A1 Recombinant herpes simplex virus, preparation method therefor and application thereof
03/13/2014WO2014036654A1 Compounds and methods for selectively targeting cancer stem cells
03/13/2014WO2014036623A1 N‑substituted chiral aromatic oxazolidines, synthesis process, pharmaceutical composition and use
03/13/2014WO2014036608A1 Methods and products for preventing and/or treating metastatic cancer
03/13/2014WO2014015137A3 Compositions and methods for treating dysproliferative diseases
03/13/2014WO2014014897A3 Immunoglobulin-binding human mycoplasma antigens and methods of use thereof
03/13/2014WO2013190508A3 1-[m-carboxamido(hetero)aryl-methyl]-heterocyclyl-carboxamide derivatives
03/13/2014WO2013188813A3 Novel therapeutics for brain cancer
03/13/2014WO2013184876A8 Benzo [c] isoxazoloazepine bromodomain inhibitors and uses thereof
03/13/2014WO2013181251A9 Crizotinib hydrochloride salt in crystalline
03/13/2014WO2013175474A9 Selective inhibitors of undifferentiated cells
03/13/2014WO2013164689A3 Humanized pan-her antibody compositions
03/13/2014US20140073686 Compositions for modulating invasion ability of a tumor and methods thereof
03/13/2014US20140073612 Transdermal delivery system kit
03/13/2014US20140073603 Phenylboronic Acid
03/13/2014US20140073047 Connective Tissue Growth Factor Antibodies
03/13/2014US20140073046 Cell Populations Which Co-Express CD49C and CD90
03/13/2014US20140072564 Therapeutic and diagnostic applications based on the role of the cxcr-4 gene in tumorigenesis
03/13/2014US20140072511 Flt4 (vegfr-3) as a target for tumor imaging and anti-tumor therapy
03/12/2014EP2706116A1 Binding domain-immunoglobulin fusion proteins
03/12/2014EP2706059A1 Diazacarbazoles and methods of use
03/12/2014EP2705857A2 Radioimmunoconjugates and uses thereof
03/12/2014EP2705855A1 Photodynamic therapy or diagnostic agent, using infrared-spectrum light
03/12/2014EP2705763A1 Method for utilizing extraction residue of yeast extract
03/12/2014EP2705039A2 Bromodomain inhibitors and uses thereof
03/12/2014EP2705032A1 Dihydroquinoline derivatives as bromodomain inhibitors
03/12/2014EP2705029A1 Novel compounds as modulators of protein kinases
03/12/2014EP2705012A1 Radiolabeled amino acids for diagnostic imaging
03/12/2014EP2704746A2 Methods for preventing toxic drug-drug interactions in combination therapies comprising anti-erbb3 agents
03/12/2014EP2704741A1 Methods for handling biological drugs containing living cells
03/12/2014EP2704735A1 Vascular disruption agents and uses thereof
03/12/2014EP2704731A1 Avian-based treatment
03/12/2014EP2704722A1 Multiple myeloma treatment
03/12/2014EP2704717A1 Method of treating cancer and bone cancer pain
03/12/2014EP2704713A1 Csf-1r inhibitors for treatment of brain tumors
03/12/2014EP2704709A1 Macrocyclic lactones and use thereof
03/12/2014EP2704700A1 Selecting use of proteasome inhibitors based on nf-kb2 sequence
03/12/2014EP2704699A1 Methods for treating prostate cancer
03/12/2014CN103635488A Anti-CD40 antibodies and methods of use
03/12/2014CN103635473A Dispiropyrrolidine derivative
03/12/2014CN103635472A Serine/threonine kinase inhibitors
03/12/2014CN103635206A Thermo-sensitive, mucoadhesive or dermoadhesive, and penetration-enhancing formulations for topical delivery of therapeutics
03/12/2014CN103635205A Photodynamic therapy using photosensitizing agent or 5-aminolevulinic acid
03/12/2014CN103635199A Herbal composition for treating cancer
03/12/2014CN103635189A Combination therapy comprising CDK4/6 inhibitor and PI3K inhibitor for use in treatment of cancer
03/12/2014CN103635187A Drug therapy to inhibit chemotherapy-induced adverse effects and related pharmaceutical compositions, diagnostics, screening techniques and kits
03/12/2014CN103635186A Inhibitors of phosphatidic acid phosphohydrolase (PAP), including D-propranolol and analogs thereof, alone or in combination with desipramine, for the treatment of cancers that depend on the epidermal growth factor receptor (EGFR), oncogenic variants thereof and other members of the ERBB/HER family
03/12/2014CN103635184A Soyasapogenol composition
03/12/2014CN103635183A Method of treating lymphoma using pyridopyrimidinone inhibitors of PI3K/MTOR
03/12/2014CN103627785A Biomarker DACT1 for gastric cancer
03/12/2014CN103627772A Preparation method of triptolide derivatives and products and application of triptolide derivatives
03/12/2014CN103627748A Preparation method of indirubin derivative and product and application thereof
03/12/2014CN103627719A Nanometer gene transfer material, and preparation method and use thereof
03/12/2014CN103627709A Deoxyribozyme capable of suppressing genetic expression of vascular endothelial growth factor
03/12/2014CN103627005A Polyethylene glycol modified polyethyleneimine and use of polyethylene glycol modified polyethyleneimine as antigen protein vector
03/12/2014CN103626882A Extraction method for duchesnea indica polysaccharide
03/12/2014CN103626881A Extraction method for plane tree bark polysaccharide
03/12/2014CN103626877A NY-ESO-1-containing fusion protein as well as preparation method and application thereof
03/12/2014CN103626871A Monoclonal antibodies capable of specifically recognizing EGFR mutant protein, preparation method and application thereof
03/12/2014CN103626865A Secreted protein with chemotactic activity, as well as coding sequence and medicament usage thereof
03/12/2014CN103626863A Oligopeptide capable of inhibiting growth of cancer cells and encoding gene thereof
03/12/2014CN103626846A Ligand polypeptide specifically combined with MDSCs (Myeloid-Derived Suppressor Cells) and drug delivery system
03/12/2014CN103626845A Arylpyrrole-2-formamide dipeptide derivatives serving as glycogen phosphorylase inhibitor and preparation method and medical application thereof
03/12/2014CN103626837A Glycogen phosphorylase inhibitor cholic acid derivative containing bio-cleavable dipeptide and preparation method and medical application thereof
03/12/2014CN103626828A Anti-tumor active ursolic acid chemical modifier and preparation method thereof
03/12/2014CN103626826A Azo bond contained glycogen phosphorylase inhibitor cholic acid derivative and preparation method and medical application thereof
03/12/2014CN103626825A Liver-targeted glycogen phosphorylase inhibitor cholic acid derivative and preparation method and medical application thereof
03/12/2014CN103626824A Hemsleya amabilis cucurbitane tetracyclic triterpene compound, pharmaceutical composition comprising compound and application of pharmaceutical composition and compound
03/12/2014CN103626801A Fostrecin (FST) derivative and medical application and preparation method thereof
03/12/2014CN103626800A Fostrecin (FST) derivative and medical application and preparation method thereof
03/12/2014CN103626787A Thienothio compound and application thereof
03/12/2014CN103626783A Dicyclic fused heterocyclic compounds, and applications and pharmaceutical compositions thereof
03/12/2014CN103626781A Targeted anti-cancer molecule gefitinib phthalocyanine conjugate, and preparation and application thereof
03/12/2014CN103626777A PLK inhibitor salts
03/12/2014CN103626776A Pyrazolo[1,5-alpha] pyrimidine nitrogen mustard derivatives, preparation methods of pyrazolo[1,5-alpha] pyrimidine nitrogen mustard derivatives, and application of pyrazolo[1,5-alpha] pyrimidine nitrogen mustard derivatives in oncotherapy
03/12/2014CN103626769A Substituted sulfydryl hexahydric heteroaromatic imidazole derivative and preparation method and application thereof
03/12/2014CN103626765A Substituted azaindole compound and salt, composition and application thereof
03/12/2014CN103626762A Benazepine compound and application thereof
03/12/2014CN103626761A Benazepine compound and application thereof as antitumor drug
1 ... 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 ... 2211